Stem cell treatment for acute myocardial infarction

Clifford, David; Fisher, Sheila; Brunskill, Susan J; Dorée, Carolyn; Mathur, Anthony; Watt, Suzanne M.; Martin‐Rendon, Enca

doi:10.1002/14651858.cd006536.pub3

Cited by 207 publications

(247 citation statements)

References 93 publications

Supporting

Mentioning

232

Contrasting

Unclassified

Order By: Relevance

“…One meta-analysis performed in 2012 of 33, randomised, controlled trials of 1765 patients who had received autologous stem or progenitor bone marrow-derived cell therapy to improve cardiac function after an acute myocardial infarction, revealed significant heterogeneity in results and reported no significant change in overall patient mortality or morbidity (as measured by hospital readmission, reinfarction or restenosis), although significant short-term improvement in left ventricular ejection fraction (LVEF) was reported, which persisted from 12-60 months. (74) Another meta-analysis published in 2015 analysed the safety and efficacy of intracoronary cell therapy after acute myocardial infarction (AMI), including individual patient data from 12 randomized trials (ASTAMI, Aalst, BOOST, BONAMI, CADUCEUS, FINCELL, REGENT, REPAIR-AMI, SCAMI, SWISS-AMI, TIME, LATE-TIME; n=1252) revealed that intracoronary cell therapy provided significant heterogeneity and no overall benefit, in terms of clinical events or changes in left ventricular function.…”

Section: Cellular Gelsmentioning

confidence: 99%

Biomaterial‐Enhanced Cell and Drug Delivery: Lessons Learned in the Cardiac Field and Future Perspectives

et al. 2016

View full text Add to dashboard Cite

Heart failure is a significant clinical issue. It is the cause of enormous healthcare costs worldwide and results in significant morbidity and mortality. Cardiac regenerative therapy has progressed considerably from clinical and preclinical studies delivering simple suspensions of cells, macromolecule, and small molecules to more advanced delivery methods utilizing biomaterial scaffolds as depots for localized targeted delivery to the damaged and ischemic myocardium. Here, regenerative strategies for cardiac tissue engineering with a focus on advanced delivery strategies and the use of multimodal therapeutic strategies are reviewed.

show abstract

Section: Cellular Gelsmentioning

confidence: 99%

Biomaterial‐Enhanced Cell and Drug Delivery: Lessons Learned in the Cardiac Field and Future Perspectives

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Glucose-insulin-potassium infusion has been purported to reduce mortality and reduce infarct size, especially for diabetic patientshowever recent trials have thrown this hypothesis into serious question [14,15].…”

Section: Pharmacotherapy For Cardioprotectionmentioning

confidence: 99%

Myocardial Infarction and Protection

Chatterjee¹

2012

J Clin Exp Cardiolog

View full text Add to dashboard Cite

“…There are currently many strategies for cardiac "cellular therapy" undergoing both preclinical and clinical trials [1][2][3][4]. While there has been modest success with improvement in cardiac function in some of the early human clinical trials, it is clear that injected or implanted cells do not survive, and functional improvement occurs via paracrine mechanisms.…”

Section: Introductionmentioning

confidence: 99%

Engineered Cardiac Tissues Generated from Immature Cardiac and Stem Cell-Derived Cells: Multiple Approaches and Outcomes

Keller

Yuan

et al. 2016

Etiology and Morphogenesis of Congenital Heart Disease

View full text Add to dashboard Cite

The translation of in vitro engineered cardiac tissues (ECTs) from immature cardiac and stem cell-derived cells toward clinical therapies is benefiting from the following major advances: (1) rapid progress in the generation of immature cardiac cells from the cardiac and noncardiac cells of multiple species including normal and disease human cells, (2) incorporation of multiple cell lineages into 3D tissues, (3) multiple scalable 3D formulations including injectable gels and implantable tissues, and (4) insights into the regulation of cardiomyocyte proliferation and functional maturation. These advances are based on insights gained from investigating the regulation of cardiac morphogenesis and adaptation. Our lab continues to explore this approach, including changes in gene expression that occur in response to mechanical loading and tyrosine kinase inhibition, the incorporation of vascular fragments into ECTs, and the fabrication of porous implantable electrical sensors for in vitro conditioning and postimplantation testing. Significant challenges remain including optimizing ECT survival postimplantation and limited evidence of ECT functional coupling to the recipient myocardium. One clear focus of current research is the optimization and expansion of the cellular constituents, including CM, required for clinical-grade ECTs. Another major area of investigation will be large animal preclinical models that more accurately represent human CV failure and that can generate data in support of regulatory approval for phase I human clinical trials. The generation of reproducible human ECTs creates the opportunity to develop in vitro myocardial surrogate tissues for novel drug therapeutics and toxicity assays.

show abstract

Stem cell treatment for acute myocardial infarction

Cited by 207 publications

References 93 publications

Biomaterial‐Enhanced Cell and Drug Delivery: Lessons Learned in the Cardiac Field and Future Perspectives

Biomaterial‐Enhanced Cell and Drug Delivery: Lessons Learned in the Cardiac Field and Future Perspectives

Myocardial Infarction and Protection

Engineered Cardiac Tissues Generated from Immature Cardiac and Stem Cell-Derived Cells: Multiple Approaches and Outcomes

Contact Info

Product

Resources

About